Armed robbers looted over Rs20 million in cash, gold, and valuables from the flat of Keamari Muktiarkar Gada Hussain Abro, a Grade-16 government officer, in DHA Phase 6 on October 27.
According to Darakhshan police SHO Shahid Taj, the robbery was allegedly orchestrated by Abro’s domestic servant, Adnan Malik, who has been arrested, while his two accomplices remain at large.
“Around 2:30pm, my wife called to inform me that armed men had entered our home and looted valuables,” Abro stated in his FIR.
He said two unidentified men knocked on the door, which was opened by the servant Adnan, allowing the robbers inside. They confined the family in one room and looted Rs15 million in cash, an iPhone 13 Pro Max, another touchscreen mobile phone, gold jewelry including two rings, three chains, a gold necklace set, a laptop, and a tablet – items collectively worth around Rs8 million.
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.
Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visit http://www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics 628-895-0661
For Media:
Jonathan Pappas LifeSci Communications 857-205-4403 [email protected]
NEW YORK, Oct. 30, 2025 — Omnicom Group Inc. (“Omnicom”) (NYSE: OMC) and The Interpublic Group of Companies, Inc. (“IPG”) (NYSE: IPG) today announced that, in connection with the closing of the merger between Omnicom and IPG expected by the end of November, Omnicom has extended the expiration date of its previously announced exchange offers and consent solicitations for IPG’s outstanding notes (as set forth in Appendix A to this press release) from 5:00 p.m., New York City time, on October 31, 2025, to 5:00 p.m., New York City time, on November 28, 2025, unless further extended. Omnicom will issue new Omnicom notes in exchange for the IPG notes as detailed in the attached Appendix A, subject to the closing of the offers and solicitations, which are conditioned upon the closing of the merger.
About Omnicom Omnicom (NYSE: OMC) is a leading provider of data-inspired, creative marketing and sales solutions. Omnicom’s iconic agency brands are home to the industry’s most innovative communications specialists who are focused on driving intelligent business outcomes for their clients. The company offers a wide range of services in advertising, strategic media planning and buying, precision marketing, retail and digital commerce, branding, experiential, public relations, healthcare marketing and other specialty marketing services to over 5,000 clients in more than 70 countries. For more information, visit www.omnicomgroup.com.
About IPG IPG (NYSE: IPG) (www.interpublic.com) is a values-based, data-fueled, and creatively driven provider of marketing solutions. Home to some of the world’s best-known and most innovative communications specialists, IPG global brands include Acxiom, Craft, FCB, FutureBrand, Golin, Initiative, IPG Health, IPG Mediabrands, Jack Morton, KINESSO, MAGNA, McCann, Mediahub, Momentum, MRM, MullenLowe Global, Octagon, UM, Weber Shandwick and more.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release contain forward-looking statements, including statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time, Omnicom or IPG or their representatives have made, or may make, forward-looking statements, orally or in writing. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of Omnicom’s and IPG’s management as well as assumptions made by, and information currently available to, Omnicom’s and IPG’s management. Forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “plan,” “could,” “should,” “would,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project” or similar words, phrases or expressions. These forward-looking statements are subject to various risks and uncertainties, many of which are outside Omnicom’s and IPG’s control. Therefore, you should not place undue reliance on such statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include:
risks relating to the pending merger between Omnicom and IPG, including: that the merger may not be completed in a timely manner or at all, which could result in the termination of the exchange offers and consent solicitations; delays, unanticipated costs or restrictions resulting from regulatory review of the merger, including the risk that Omnicom or IPG may be unable to obtain governmental and regulatory approvals required for the merger, or that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger; uncertainties associated with the merger may cause a loss of both companies’ management personnel and other key employees, and cause disruptions to both companies’ business relationships and a loss of clients; the merger agreement subjects Omnicom and IPG to restrictions on business activities prior to the effective time of the merger; Omnicom and IPG are expected to incur significant costs in connection with the merger and integration; litigation risks relating to the merger; the business and operations of both companies may not be integrated successfully in the expected time frame; the merger may result in a loss of both companies’ clients, service providers, vendors, joint venture participants and other business counterparties; and the combined company may fail to realize all or some of the anticipated benefits of the merger or fail to effectively manage its expanded operations;
adverse economic conditions and disruptions, including geopolitical events, international hostilities, acts of terrorism, public health crises, inflation or stagflation, tariffs and other trade barriers, central bank interest rate policies in countries that comprise Omnicom’s and IPG’s major markets, labor and supply chain issues affecting the distribution of clients’ products, or a disruption in the credit markets;
international, national or local economic conditions that could adversely affect Omnicom, IPG or their respective clients;
losses on media purchases and production costs incurred on behalf of clients;
reductions in client spending, a slowdown in client payments or a deterioration or disruption in the credit markets;
the ability to attract new clients and retain existing clients in the manner anticipated;
changes in client marketing and communications services requirements;
failure to manage potential conflicts of interest between or among clients;
unanticipated changes related to competitive factors in the marketing and communications services industries;
unanticipated changes to, or the ability to hire and retain key personnel;
currency exchange rate fluctuations;
reliance on information technology systems and risks related to cybersecurity incidents;
effective management of the risks, challenges and efficiencies presented by utilizing artificial intelligence (AI) technologies and related partnerships;
changes in legislation or governmental regulations affecting Omnicom, IPG or their respective clients;
risks associated with assumptions made in connection with acquisitions, critical accounting estimates and legal proceedings;
risks related to international operations, which are subject to the risks of currency repatriation restrictions, social or political conditions and an evolving regulatory environment in high-growth markets and developing countries;
risks related to environmental, social and governance goals and initiatives, including impacts from regulators and other stakeholders, and the impact of factors outside of Omnicom’s and IPG’s respective control on such goals and initiatives;
the outcome of the exchange offers and consent solicitations; and
other business, financial, operational and legal risks and uncertainties detailed from time to time in Omnicom’s and IPG’s Securities and Exchange Commission (“SEC”) filings.
The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that may affect Omnicom’s and IPG’s businesses, including those described in Omnicom’s and IPG’s respective Annual Reports on Form 10-K and in other documents filed from time to time with the SEC. Forward-looking statements are based on the estimates and opinions of management at the time the statements are made. Except to the extent required by applicable law, neither Omnicom nor IPG undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
NO OFFER OR SOLICITATION
This communication is not intended to and does not constitute an offer to purchase, or the solicitation of an offer to sell, or the solicitation of tenders or consents with respect to any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In the case of the exchange offers and consent solicitations, the exchange offers and consent solicitations are being made solely pursuant to the Statement (as defined in Appendix A) and only to such persons and in such jurisdictions as is permitted under applicable law.
Appendix A
Omnicom hereby extends the expiration date of its previously announced Exchange Offers and Consent Solicitations for the Existing IPG Notes (each as defined below) from 5:00 p.m., New York City time, on October 31, 2025, to 5:00 p.m., New York City time, on November 28, 2025, unless further extended (the “Expiration Date”).
The (A) offers to exchange (each an “Exchange Offer” and, collectively the “Exchange Offers”) any and all outstanding 4.650% Notes due 2028 (the “Existing IPG 2028 Notes”), 4.750% Notes due 2030 (the “Existing IPG 2030 Notes”), 2.400% Notes due 2031 (the “Existing IPG 2031 Notes”), 5.375% Notes due 2033 (the “Existing IPG 2033 Notes”), 3.375% Notes due 2041 (the “Existing IPG 2041 Notes”) and 5.400% Notes due 2048 (the “Existing IPG 2048 Notes” and, together with the Existing IPG 2028 Notes, the Existing IPG 2030 Notes, the Existing IPG 2031 Notes, the Existing IPG 2033 Notes and the Existing IPG 2041 Notes, the “Existing IPG Notes”), each series as issued by IPG, for (1) up to $2,950,000,000 aggregate principal amount of new senior notes to be issued by Omnicom (the “New Omnicom Notes”) and (2) cash; and (B) related solicitations of consents on behalf of IPG (each a “Consent Solicitation” and, collectively, the “Consent Solicitations”) from Eligible Holders (as defined below) of a majority in aggregate principal amount outstanding of each series of Existing IPG Notes, to amend each indenture governing each series of Existing IPG Notes (each an “Existing IPG Indenture” and, collectively, the “Existing IPG Indentures”) are made pursuant to the terms and subject to the conditions set forth in the offering memorandum and consent solicitation statement, dated August 11, 2025 (the “Statement”).
As of 5:00 p.m., New York City time, on October 29, 2025, the principal amounts of Existing IPG Notes set forth in the table below had been validly tendered and not validly withdrawn (and consents thereby validly delivered and not validly revoked).
Title of Series of Existing IPG Notes
CUSIP Number of Existing IPG Notes
Title Series of New Omnicom Notes
Aggregate Principal Amount Outstanding
Existing IPG Notes Tendered
Principal Amount
Percentage
4.650% Notes due 2028
460690BP4
4.650% Senior Notes due 2028
$500,000,000
$449,857,000
89.97 %
4.750% Notes due 2030
460690BR0
4.750% Senior Notes due 2030
$650,000,000
$591,955,000
91.07 %
2.400% Notes due 2031
460690BT6
2.400% Senior Notes due 2031
$500,000,000
$457,083,000
91.42 %
5.375% Notes due 2033
460690BU3
5.375% Senior Notes due 2033
$300,000,000
$276,504,000
92.17 %
3.375% Notes due 2041
460690BS8
3.375% Senior Notes due 2041
$500,000,000
$494,141,000
98.83 %
5.400% Notes due 2048
460690BQ2
5.400% Senior Notes due 2048
$500,000,000
$491,619,000
98.32 %
$2,950,000,000
$2,761,159,000
93.60 %
On the early tender date and consent revocation deadline of August 22, 2025, Omnicom received consents sufficient to amend the respective Existing IPG Indentures to eliminate certain of the covenants, restrictive provisions and events of default from such Existing IPG Indentures (collectively, the “Proposed Amendments”). On August 22, 2025, IPG executed a supplemental indenture (the “New IPG Supplemental Indenture”) to the Existing IPG Indentures in order to effect the Proposed Amendments. The Proposed Amendments included in the New IPG Supplemental Indenture will become operative (i) only upon the settlement date for the Exchange Offers and the Consent Solicitations, which is expected to be within two business days after the Expiration Date and (ii) subject to satisfaction or waiver of certain conditions, including the completion of Omnicom’s pending transaction to acquire IPG contemplated by the Agreement and Plan of Merger, dated as of December 8, 2024 (such transaction, the “Merger”). Omnicom may waive any such condition at any time with respect to an Exchange Offer (other than the condition that the Merger shall have been completed).
The settlement date is expected to be within two business days after the Expiration Date. To the extent the completion of the Merger is not anticipated to occur on or before the Expiration Date, for any reason, Omnicom anticipates further extending the Expiration Date until such time that the Merger has been completed. Any such extension of the Expiration Date will correspondingly extend the settlement date. Omnicom will provide notice of any such extension in advance of the Expiration Date. During any extension of the Expiration Date, all Existing IPG Notes not previously tendered (or validly withdrawn) in an extended Exchange Offer will remain subject to such Exchange Offer and may be accepted for exchange by Omnicom. Following receipt of the requisite consents and the execution of the New IPG Supplemental Indenture on August 22, 2025, consents delivered in the Consent Solicitations with respect to each series of Existing IPG Notes can no longer be revoked.
The Statement and other documents relating to the Exchange Offers and Consent Solicitations will only be distributed to holders of Existing IPG Notes who complete and return a letter of eligibility certifying that they are (i) “qualified institutional buyers” within the meaning of Rule 144A under the Securities Act of 1933, as amended (“Securities Act”), or (ii) not “U.S. persons” and are outside of the United States within the meaning of Regulation S under the Securities Act and who are “non-U.S. qualified offerees” (as defined in the Statement) (such persons, “Eligible Holders”). Only Eligible Holders are authorized to receive and review the Statement and only Eligible Holders are permitted to tender Existing IPG Notes in the Exchange Offers and deliver consents in the Consent Solicitations. Eligible Holders of Existing IPG Notes who desire to obtain and complete the letter of eligibility and obtain copies of the Statement should call D.F. King & Co., Inc., the Exchange and Information Agent, at (800) 290-6432 (toll-free) or (212) 401-9970 (collect for banks and brokers). Information related to the Exchange Offers and Consent Solicitations, together with any updates, will be available at www.dfking.com/omnicom.
Except as described in this press release and the joint press releases issued by Omnicom and IPG on September 9, 2025 and September 30, 2025, all other terms of the Exchange Offers and Consent Solicitations remain unchanged.
Among other risks described in the Statement, the Exchange Offers and Consent Solicitations are expected to result in reduced liquidity for the Existing IPG Notes that are not exchanged, and the Proposed Amendments to the Existing IPG Indenture will reduce protection to remaining holders of Existing IPG Notes. Eligible Holders should refer to the Statement for more details on the risks related to the Exchange Offers and Consent Solicitations.
Omnicom has engaged BofA Securities, Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as lead dealer managers and solicitation agents (the “Lead Dealer Managers”) and each of Barclays Capital Inc., BNP Paribas Securities Corp., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and HSBC Securities (USA) Inc., as co-dealer managers (together, the “Co-Dealer Managers” and together with the Lead Dealer Managers, the “Dealer Managers”) for the Exchange Offers and Consent Solicitations. Please direct questions regarding the Exchange Offers and Consent Solicitations to BofA Securities, Inc. at (888) 292-0070 (toll-free) or (980) 387-3907 (collect for banks and brokers), J.P. Morgan Securities LLC at (866) 834-4666 (toll-free) or (212) 834-3554 (collect for banks and brokers) or Wells Fargo Securities, LLC at (866) 309-6316 (toll free) or (332) 214-6330.
The New Omnicom Notes have not been registered under the Securities Act or any state or foreign securities laws, and they may not be offered or sold absent registration except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable state and foreign securities laws. The Statement has not been filed with or reviewed by the federal or any state securities commission or regulatory authority of any country, nor has any such commission or authority passed upon the accuracy or adequacy of the Statement. Any representation to the contrary is unlawful and may be a criminal offense.
None of Omnicom, IPG, any of their respective directors or officers, the Dealer Managers or the Exchange and Information Agent, or in each case, any of their respective affiliates, makes any recommendation as to whether or not Eligible Holders should tender or refrain from tendering all or any portion of the Existing IPG Notes in response to the Exchange Offers, or deliver consents in response to the Consent Solicitations. Eligible Holders will need to make their own decision as to whether to tender Existing IPG Notes in the Exchange Offer and participate in the Consent Solicitations and, if so, the principal amount of Existing IPG Notes to tender.
The sale supports Celanese’s strategic priorities, including deleveraging its balance sheet and focusing on core growth areas.
The Micromax portfolio comprises advanced electronic inks and pastes used in high performance electronics across applications such as navigation and defense, medical monitoring, and advanced circuit board components. The portfolio includes conductive, resistive, and dielectric thick film inks, as well as Low Temperature Co fired Ceramic (LTCC) materials for multilayer circuits.
The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions and required regulatory approvals.
“This transaction underscores our strength in executing complex, cross border divestitures,” said M&A partner, Romain Dambre. “We are pleased to support Celanese on a strategic portfolio action that advances its priorities and positions Micromax for continued success under new ownership.”
The A&O Shearman team that advised Celanese was led by M&A partner, Romain Dambre and associates Iqra Anees, Lucy Chen, and Becca Scher in New York.
Tax advice was provided by partner Ryan Bray in Dallas, and associate Brandon Fawbush in Washington D.C. Antitrust advice was provided by partner Noah Brumfield and associate Nick Putz in Washington D.C. Employment advice was provided by compensation, employment, pensions and governance (CEPG) partners Doreen Lilienfeld and Melisa Brower and associates Alexandra Sentner and Thomas Blecher in New York. Intellectual property advice was provided by partner JB Betker and associate Will Jackson in New York.
The multidisciplinary deal team was also supported by A&O Shearman teams across nine jurisdictions, including U.S., UK, China, France, Germany, Hong Kong, Japan, Netherlands, and Singapore.
A fully-fledged digital euro should only be launched if the private sector doesn’t come up with its own solution to integrate the region’s fractured payments landscape, according to the lead European Union lawmaker on the file.
Fernando Navarrete proposed to let an online version of the digital money be “conditional on the absence of a pan-European sovereign retail payment solution,” according to a statement accompanying the long-awaited report that will form the basis for further discussions in the European Parliament.
Crystal Lake, Illinois, October 30, 2025 — AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, today reported the following third quarter results for the period ended September 30, 2025, as compared to the corresponding period of the last fiscal year.
Third Quarter 2025 Highlights
(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)
Reported sales increased 6% and core sales increased 1%
Strong product volume growth in Closures and Pharma, especially in injectables
Reported net income increased 28% to $128 million and reported earnings per share increased 30% to $1.92
Adjusted earnings per share, which also excludes non-ordinary-course litigation costs (see Non-GAAP section for full definition), increased 4% to $1.62
Adjusted EBITDA, which also excludes non-ordinary-course litigation costs, increased 7% to $223 million
Adjusted EBITDA margin was 23.2% compared to 22.9% in the prior year
Returned $70 million to shareholders through share repurchases and dividends
Nine Months Year-to-Date 2025 Highlights
(Compared to the prior year period; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)
Reported sales increased 3% and core sales increased 1%
Reported net income increased 16% to $318 million and reported earnings per share increased 17% to $4.75
Adjusted earnings per share increased 7% to $4.48
Adjusted EBITDA increased 8% to $624 million, and Adjusted EBITDA margin was 22.2% compared to 21.2% in the prior year
Returned $279 million to shareholders through share repurchases and dividends
“Aptar delivered solid third quarter results with strong product volume growth in Pharma and Closures. As we anticipated, we are seeing the steady ramp in sales in our injectables division, which grew 18% in the third quarter, indicating an expected strong finish to the year for elastomeric components. Our continued focus on innovation, operational excellence and disciplined capital deployment, positions us well to deliver sustainable value for our customers and shareholders, while expanding our third quarter adjusted EBITDA margin,” said Stephan B. Tanda, Aptar President and CEO.
Your guide to what Trump’s second term means for Washington, business and the world
The Federal Reserve’s top banking supervisor plans to shrink the Washington-based board’s staff by 30 per cent, amid a push by the Trump administration to deregulate the financial sector.
Michelle Bowman, the Fed’s vice-chair for supervision, on Thursday unveiled a proposal to lower the headcount of the central bank’s supervision and regulation department from 500 to roughly 350 employees by the end of 2026.
An email sent to staff, seen by the Financial Times, said the central bank would try to lower headcount “as much as possible through natural attrition, retirements, and by offering a voluntary separation incentive to all S&R division employees, with details to come in the following weeks”.
The email also highlighted Bowman’s plans to reshape the unit “to operate with a flatter organizational structure and fewer management layers”.
The lay-offs will only affect staff based at the Fed board, and not the 12 regional Feds, where most of the central bank’s supervisors work.
The changes come as the Trump administration pushes the Fed and other US financial regulators to ease rules affecting American lenders.
Elizabeth Warren, the most senior Democrat on the powerful Senate Banking Committee, which oversees the Fed, accused the central bank of “recycling” a regime that contributed to the 2008 global financial crisis.
“The agency is now gutting its supervision and regulation staff, while granting big banks their deregulatory wish list. The Fed is actively undermining American financial stability at a moment when Donald Trump is taking a wrecking ball to our economy,” Warren said.
“We all know what happened the last time we let Wall Street run rampant, and I’m deeply concerned American families will pay the price once again.”
Bowman is one of five candidates on Treasury secretary Scott Bessent’s shortlist to become Fed chair when Jay Powell’s second term at the helm of the central bank ends in May 2026. US President Trump has said he plans to announce his replacement for Powell by the end of this year.
The regulatory changes the Fed is considering could enable banks to lower their capital ratios enough to offer US borrowers an additional $2.6tn in lending capacity, according to consultancy Alvarez & Marsal.
Bessent has also criticised the Dodd-Frank legislation, which was introduced after the global financial crisis of 2008 and expanded the Fed’s supervision and regulation responsibilities, for giving the central bank too much control over US lenders.
“The core problem is structural: the Fed now regulates, lends to and sets the profitability calculus for the very banks it oversees,” Bessent said in an International Economy magazine article in September. “This is an unavoidable conflict that blurs accountability and jeopardizes monetary policy independence.”
Amazon has made its first financial disclosures since the disastrous outage suffered by its cloud computing division that brought everything from smart beds to banks offline.
In spite of the global outage, Amazon Web Services has continued to grow, and this quarter reported a 20% increase in revenue year over year. Wall Street estimated that AWS would bring in $32.42bn in net sales in the third quarter, with the company reporting actual revenue of $33bn.
“AWS is growing at a pace we haven’t seen since 2022,” CEO Andy Jassy said in a statement accompanying the earnings report.
The strong third-quarter earnings, which exceeded analysts’ expectations, led the company’s stock to spike up about 9% in after-hours trading.
The earnings report highlighted Amazon’s desire to compete with competitors that have managed to capitalize more aggressively on the AI boom. Amazon’s stock has lagged behind some rivals in big tech, and its e-commerce business has been more susceptible to the effects of the Trump administration’s sweeping and unpredictable tariff policies than firms more focused on software.
The tech company, worth some $2.4tn, revealed that it easily beat Wall Street expectations through growth in its cloud computing services. Market analysts had predicted that Amazon would report $1.58 earnings per share and a net sales revenue of $177.82bn. The company reached $180.17bn in revenue and $1.95 earnings per share.
AWS has faced increasing competition from alternative providers such as Google Cloud and Microsoft Azure, with the latter’s partnership with OpenAI and reports of strong growth in its cloud business driving up its share price.
Yet AWS is still a backbone of much of the modern internet, with an inadvertent show of its power taking place earlier this month when a glitch in the company’s cloud computing took websites, apps, tech products and critical communications systems, such as electronic hospital records, offline. The outage affected millions of people and lasted hours, underscoring how reliant many parts of everyday life are on Amazon’s products.
At Amazon headquarters, the company confirmed plans earlier this week to lay off 14,000 corporate workers, while further job cuts are expected throughout the company. The tech company publicly announced the cuts in a post on its website titled “Staying nimble and continuing to strengthen our organizations”, which referenced advancements in AI and claimed the company wanted to “operate like the world’s largest startup”.
skip past newsletter promotion
after newsletter promotion
“What we need to remember is that the world is changing quickly,” Amazon’s post stated. “This generation of AI is the most transformative technology we’ve seen since the Internet, and it’s enabling companies to innovate much faster than ever before.”
Jassy suggested in a blog post earlier this year that the company’s investments in AI would mean that Amazon needs “fewer people doing some of the jobs that are being done today”.
PALM BEACH GARDENS, Fla., Oct. 30, 2025 /PRNewswire/ — Carrier Global Corporation (NYSE: CARR) Chairman & CEO David Gitlin and Senior Vice President & CFO Patrick Goris will speak at the Baird 2025 Global Industrial Conference on Wednesday, November 12, 2025, at 12:00 p.m. CT (1:00 p.m. ET).
The event will be broadcast live at ir.carrier.com. A webcast replay will be available on the website following the event.
About Carrier
Carrier Global Corporation, global leader in intelligent climate and energy solutions, is committed to creating innovations that bring comfort, safety and sustainability to life. Through cutting-edge advancements in climate solutions such as temperature control, air quality and transportation, we improve lives, empower critical industries and ensure the safe transport of food, life-saving medicines and more. Since inventing modern air conditioning in 1902, we lead with purpose: enhancing the lives we live and the world we share. We continue to lead because of our world-class, inclusive workforce that puts the customer at the center of everything we do. For more information, visit corporate.carrier.com or follow Carrier on social media at @Carrier.
